James Murdoch steps down from GSK board
Published on: 27/01/12
GlaxoSmithKline has announced that after nine years with the firm, Sir Crispin Davis, Sir Robert Wilson and Larry Culp will stand down from the board.
In addition, the UK firm said that James Murdoch has decided not to stand for re-election.
Sir Christopher Gent, chairman of GSK, said: “James Murdoch has decided to stand down from the board with effect from this year’s AGM.
“James has taken this decision to focus on his current duties as non-executive chairman of BSkyB, and following his decision to relocate to the US, as chairman and chief executive, International, of News Corporation.
“On behalf of the board, I would like to thank James for the very strong contribution he has made since he was appointed in 2009 and wish him well.”
Tom de Swaan will now succeed Sir Crispin Davis as chairman of the remuneration committee with effect from 1 January 2013.
From the same date Judy Lewent will succeed Tom de Swaan as chair of the audit and risk committee, and Sir Deryck Maughan will succeed Sir Robert Wilson as senior independent on-executive director.
Mission Statement
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma jobs, pharma events, and pharma service company listings.
Site content is produced by our editorial team for InPharm.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
